Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Scheinberg

Showing results (1-10 of 172) with videos related to

Pageof 18
Sort By:
Blood|March 4, 2017
Immune reconstitution and remission in CMLDavid A Scheinberg
Haematologica|October 13, 2005
Immune surveillance of leukemia?David A Scheinberg
Best Practice & Research. Clinical Haematology|September 16, 2008
Peptide vaccines for myeloid leukaemiasTao Dao, David A Scheinberg
Seminars in Radiation Oncology|March 2, 2011
Will nanotechnology influence targeted cancer therapy?Jan Grimm, David A Scheinberg
Current Radiopharmaceuticals|December 29, 2011
Actinium-225 in targeted alpha-particle therapeutic applicationsDavid A Scheinberg, Michael R McDevitt
Critical Reviews in Oncogenesis|October 2, 2014
Fibrillous carbon nanotube: an unexpected journeyMichael R McDevitt, David A Scheinberg
Molecular Pharmaceutics|January 8, 2009
Meeting report: drug carriers in medicine and biologyPeter D Senter, David A Scheinberg
Oncotarget|June 27, 2013
Reaching un-drugable intracellular targets with the long arm of antibodiesDavid A Scheinberg, Tao Dao, Cheng Liu
Oncoimmunology|September 28, 2013
Approaching untargetable tumor-associated antigens with antibodiesTao Dao, Cheng Liu, David A Scheinberg
Expert Opinion on Biological Therapy|September 3, 2013
Therapeutic antibodies to intracellular targets in cancer therapyNicholas Veomett, Tao Dao, David A Scheinberg
Pageof 18

Showing results (1-10 of 172) with videos related to

Sort By:
Pageof 18
Blood|March 4, 2017
Immune reconstitution and remission in CMLDavid A Scheinberg
Haematologica|October 13, 2005
Immune surveillance of leukemia?David A Scheinberg
Best Practice & Research. Clinical Haematology|September 16, 2008
Peptide vaccines for myeloid leukaemiasTao Dao, David A Scheinberg
Seminars in Radiation Oncology|March 2, 2011
Will nanotechnology influence targeted cancer therapy?Jan Grimm, David A Scheinberg
Current Radiopharmaceuticals|December 29, 2011
Actinium-225 in targeted alpha-particle therapeutic applicationsDavid A Scheinberg, Michael R McDevitt
Critical Reviews in Oncogenesis|October 2, 2014
Fibrillous carbon nanotube: an unexpected journeyMichael R McDevitt, David A Scheinberg
Molecular Pharmaceutics|January 8, 2009
Meeting report: drug carriers in medicine and biologyPeter D Senter, David A Scheinberg
Oncotarget|June 27, 2013
Reaching un-drugable intracellular targets with the long arm of antibodiesDavid A Scheinberg, Tao Dao, Cheng Liu
Oncoimmunology|September 28, 2013
Approaching untargetable tumor-associated antigens with antibodiesTao Dao, Cheng Liu, David A Scheinberg
Expert Opinion on Biological Therapy|September 3, 2013
Therapeutic antibodies to intracellular targets in cancer therapyNicholas Veomett, Tao Dao, David A Scheinberg
Pageof 18